menu
    • menu

    Company profile for VistaGen Therapeutics

    NEW Drugs in Dev: 8
    FAMAR CDMO- From early development to commercial manufacturing.

    Virtual Booth

    Contact Supplier

    Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    Contact Supplier

    AbbVie Contract Manufacturing partners globally to develop, scale, and manufacture pharmaceutical products successfully.

    Virtual Booth

    Contact Supplier

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    VistaGen Therapeutics, Inc. (NASDAQ: VTGN), is a clinical-stage biopharmaceutical company developing new generation medicines for central nervous system (CNS) diseases and disorders with high unmet need, including major depressive disorder, neuropathic pain social anxiety disorder and suicidal ideation.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    VistaGen TherapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    343 Allerton Avenue South San Francisco, CA 94080
    Telephone
    Telephone
    (650) 577-3600
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.vistagen.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    PEGS Boston Summit

    PEGS Boston Summit

    Not Confirmed

    envelop Contact Supplier

    PEGS Boston Summit

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Vistagen Taps Dr. Angel Angelov As Chief Medical Officer
    Vistagen Taps Dr. Angel Angelov As Chief Medical Officer

    19 May 2026

    // CONTRACTPHARMA

    https://www.contractpharma.com/breaking-news/vistagen-taps-dr-angel-angelov-as-chief-medical-officer/

    CONTRACTPHARMA
    19 May 2026
    Share Share
    Vistagen Completes PALISADE-4 Phase 3 Dosing for Social Anxiety
    Vistagen Completes PALISADE-4 Phase 3 Dosing for Social Anxiety

    08 May 2026

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2026-05-08/vistagen-announces-completion-of-last-patient-visit-in-palisade-4-phase-3-public-speaking-challenge

    PHARMIWEB
    08 May 2026
    Share Share
    Vistagen To Join 46th TD Cowen Healthcare Conference
    Vistagen To Join 46th TD Cowen Healthcare Conference

    25 Feb 2026

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20260225291027/en/Vistagen-to-Participate-in-the-46th-Annual-TD-Cowen-Healthcare-Conference

    BUSINESSWIRE
    25 Feb 2026
    Share Share
    Vistagen Reveals Fy2026 Q3 Financials And Corporate Update
    Vistagen Reveals Fy2026 Q3 Financials And Corporate Update

    12 Feb 2026

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20260212959012/en/Vistagen-Reports-Fiscal-Year-2026-Third-Quarter-Financial-Results-and-Provides-Corporate-Update

    BUSINESSWIRE
    12 Feb 2026
    Share Share
    Vistagen To Host Q3 Fiscal Year 2026 Results Conference Call
    Vistagen To Host Q3 Fiscal Year 2026 Results Conference Call

    04 Feb 2026

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20260204838058/en/Vistagen-to-Report-Fiscal-Year-2026-Third-Quarter-Results-and-Host-Corporate-Update-Conference-Call-on-February-12-2026

    BUSINESSWIRE
    04 Feb 2026
    Share Share
    Vistagen's Social Anxiety Disorder Asset Stumbles In Phase 3
    Vistagen's Social Anxiety Disorder Asset Stumbles In Phase 3

    18 Dec 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251217824138/en/Vistagen-Announces-Topline-Results-from-PALISADE-3-Phase-3-Public-Speaking-Challenge-Study-of-Fasedienol-for-the-Acute-Treatment-of-Social-Anxiety-Disorder

    BUSINESSWIRE
    18 Dec 2025
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search